| Exhibit 99.1 2100 EAST 54TH STREET NORTH |
SAB Biotherapeutics Provides Company Update
and Reports Full Year 2021 Financial Results
SAB executing on its strategy to build a proprietary immune and autoimmune disorders pipeline, including respiratory diseases that affect immunocompromised patients
Plans to announce full data from Phase 2a trial that evaluated SAB-176 for the treatment of seasonal influenza mid-2022 – first full clinical data set from DiversitAb platform
SAB continues to advance on Rapid Response Antibody Program collaboration with
US Department of Defense
Generated robust data set, demonstrated proof-of-concept and validated platform through accelerated clinical development of SAB-185, a high-potency fully-human polyclonal therapeutic, to address pandemic need for novel treatments against emerging biothreats, respiratory viruses and viral mutations
Sufficient cash and government funding anticipated to operate through third quarter 2023
Sioux Falls, S.D., March 29, 2022 – SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today provided a business update and reported financial results for the full year ended December 31, 2021.
“2021 was a pivotal year for SAB Biotherapeutics, as we successfully closed our business combination and debuted on the NASDAQ exchange, while advancing SAB-185 and SAB-176, our novel polyclonal antibodies for COVID-19 and influenza. Our work on SAB-185 propelled our science forward with a real-world proof-of-concept. It contributed greatly to our scientific knowledge and gave us tremendous confidence in what SAB can achieve with our innovative technology to address a variety of acute and chronic unmet medical needs. It also demonstrated the potential of our rapid response platform to address future global public health threats. The historic impact of influenza and the evolving COVID-19 pandemic continues to impact at-risk patients, such as those with underlying conditions or those who are immunocompromised. The need for potent therapeutics remains clear,” said Eddie J. Sullivan, Ph.D., co-founder, President and Chief Executive Officer of SAB Biotherapeutics. “We are extremely proud of our team and SAB’s role in responding to the COVID-19 health crisis. SAB remains dedicated to rapidly developing therapies that can play a role in both this pandemic and in future threats to public health.”
Dr. Sullivan continued, “Moving forward into 2022, we remain focused on leveraging the breadth of the platform to monetize both our pipeline programs and those outside our core therapeutic focus, including respiratory disease, oncology and monoclonal discovery. We continue to execute on the Rapid Response Antibody Program through our contract with the US Department of Defense, initiated in 2019, which has expanded and advanced significantly due to the accelerated progress made during the COVID-19 pandemic response. We also remain on track to release initial proof-of-principle data in demonstrating the potential of multi-targeted human polyclonals in oncology. With multiple milestones rapidly approaching, including the first clinical data from our platform, and the anticipated readout of the full dataset from our Phase 2a study of SAB-176 in seasonal influenza, we believe we are well positioned to deliver on the promise of our strategy to continue building a robust pipeline spanning immune and autoimmune disorders, and bringing much needed therapeutics to patients.”
| Exhibit 99.1 2100 EAST 54TH STREET NORTH |
2021 and Pipeline Updates and 2022 Anticipated Milestones
| Exhibit 99.1 2100 EAST 54TH STREET NORTH |
2021 Highlights and Strategy Update
| Exhibit 99.1 2100 EAST 54TH STREET NORTH |
Full Year 2021 Financial Results
Financial Guidance: Based on its current operating plans, SAB expects that its existing cash, cash equivalents and its U.S. Government funding as of December 31, 2021, will be sufficient to fund its operating expenses and capital expenditure requirements into the third quarter of 2023.
| Exhibit 99.1 2100 EAST 54TH STREET NORTH |
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies with a focus on building a leading immune and autoimmune disorders pipeline. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ that produce fully human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune and autoimmune disorders including type 1 diabetes and organ transplantation, and cancer. SAB’s versatile DiversitAb™ platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB currently has multiple drug development programs underway and collaborations with the US government and global pharmaceutical companies. For more information on SAB, visit: https://www.sabbiotherapeutics.com/ and follow @SABBantibody on Twitter.
Investor Relations and Media Contact:
Melissa Ullerich
+1 605-679-4609
mullerich@sabbiotherapeutics.com
Forward-Looking Statements
Certain statements made herein that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including the development and efficacy of SAB-185, our influenza program and other discovery programs, our cash runaway into 2023 and potential future government and third-party collaborations or funded programs.
These statements are based on the current expectations of SAB and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict, will differ from assumption and are beyond the control of SAB. A further description of risks and uncertainties can be found in the prospectus filed by SAB Biotherapeutics, Inc. on December 29, 2021, including in the sections thereof captioned “Risk Factors” as well as in its subsequent reports on Form 10-K, 10-Q and Form 8-K, all of which will be filed with the U.S. Securities and Exchange Commission and available at https://www.sec.gov/